Quince Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

IRulya Therapeutics

14/08/2026 15:11

Quince Therapeutics, Inc. QNCX.OQ reported a quarterly adjusted loss of $12.31​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-46.00.  The mean expectation of three analysts for the quarter was for a loss of $17.88 per share. Wall Street expected results to range from $-33.26 to $-2.50 per share.
Reported revenue was zero​; analysts expected zero. 
Quince Therapeutics, Inc.'s reported EPS for the quarter was a loss of $12.31​.
The company reported a quarterly loss of $75.49 million.
Quince Therapeutics, Inc. shares had risen by 78.2% this quarter and lost 95.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 66% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Quince Therapeutics, Inc. is $81.00, about 60% above its last closing price of $32.41
This summary was machine generated from LSEG data August 14 at 02:10 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-17.88
-12.31
Beat
Mar. 31 2026 
-51.20
57.60
Beat
Dec. 31 2025 
-37.76
-1.42 hundred
Missed
Sep. 30 2025 
-43.28
-50.00
Missed